Export

EN
FR
Amodiaquine - sulfadoxine + pyrimethamine
Essential medicine status
Section:
6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.2. Antimalarial medicines > Medicines for chemoprevention
ATC codes: P01BA06 P01BD51
EMLc
Indication
Malaria ICD11 code: 1F4Z
INN
Amodiaquine + sulfadoxine + pyrimethamine
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc) ; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc)
EML status history
First added in 2019 (TRS 1021)
Changed in 2025 (TRS 1064)
Sex
All
Age
Children (1 month - 12 years)
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Amodiaquine - sulfadoxine + pyrimethamine
DrugBank
Amodiaquine ,
Sulfadoxine ,
Pyrimethamine
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strengths of co-packaged amodiaquine with sulfadoxine + pyrimethamine to the EMLc for seasonal malaria chemoprevention in children.